HighTower Advisors’s Collegium Pharmaceutical COLL Stock Holding History

HighTower Advisors’s Portfolio COLL Stock Details COLL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$306K	Sell	8,451 -2,702	-24%	-$92.3K	﹤0.01%	3197
2026 Q1	$369K	Buy	11,153 +5,092	+84%	+$216K	﹤0.01%	2984
2025 Q4	$281K	Buy	+6,061	New	+$254K	﹤0.01%	3096
2025 Q3	–	Sell	-10,657	Closed	-$315K	–	3874
2025 Q2	$315K	Sell	10,657 -460	-4%	-$13.1K	﹤0.01%	2891
2025 Q1	$332K	Sell	11,117 -3,839	-26%	-$117K	﹤0.01%	2780
2024 Q4	$428K	Sell	14,956 -441	-3%	-$14.6K	﹤0.01%	2592
2024 Q3	$608K	Buy	15,397 +252	+2%	+$8.99K	﹤0.01%	2256
2024 Q2	$490K	Sell	15,145 -463	-3%	-$16.1K	﹤0.01%	2342
2024 Q1	$615K	Buy	+15,608	New	+$546K	﹤0.01%	2127
2023 Q1	–	Sell	-19,596	Closed	-$463K	–	3461
2022 Q4	$463K	Buy	+19,596	New	+$395K	﹤0.01%	2178

Other funds holding COLL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

HighTower Advisors's COLL Position: Q2 2026 in Review

HighTower Advisors reduced its Collegium Pharmaceutical (COLL) stake by 24% in Q2 2026, selling an estimated $92.3K and leaving 8,451 shares worth $306K. The position accounts for ﹤0.01% of the portfolio, ranked #3197.

HighTower Advisors first reported a position in COLL in Q4 2022 and has held it in 10 quarters since. The position peaked at $615K in Q1 2024. 279 funds tracked by Wall St. Rank hold COLL as of Q2 2026.

HighTower Advisors held 8,451 shares of Collegium Pharmaceutical worth $306K as of Q2 2026.
HighTower Advisors sold 2,702 Collegium Pharmaceutical shares in Q2 2026, an estimated $92.3K.
Collegium Pharmaceutical made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3197 holding.
HighTower Advisors first reported a position in Collegium Pharmaceutical in Q4 2022 and has held it in 10 quarters since.
HighTower Advisors's Collegium Pharmaceutical position peaked at $615K in Q1 2024.
279 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.